How FTO and ALKBH5 Erase Epigenetic Marks
Beneath the elegant simplicity of DNA's double helix lies a complex world of RNA regulation, governed by chemical modifications that fine-tune genetic expression. Among these, N6-methyladenosine (m6A) stands as the most abundant internal modification in eukaryotic mRNA, acting like a molecular switch that controls RNA fate. But this mark isn't permanentâit can be erased. Enter FTO and ALKBH5, the only known human m6A "erasers." These enzymes are Fe(II)/α-ketoglutarate-dependent dioxygenases that surgically remove methyl groups from adenosine, dynamically reshaping the cellular landscape. Their structures, recently decoded through cutting-edge crystallography, reveal not just how they work, but how they discriminate between thousands of RNA transcriptsâa discovery with profound implications for cancer, obesity, and neurological disorders 1 3 8 .
Both FTO and ALKBH5 belong to the AlkB dioxygenase family, characterized by a conserved catalytic core: the double-stranded β-helix (DSBH) fold. This eight-stranded "jelly-roll" scaffold anchors their active sites:
Feature | FTO | ALKBH5 |
---|---|---|
Size | 505 residues | 395 residues |
Key Domains | NTD (DSBH), CTD (helix bundle) | DSBH core, NRL1/NRL2 loops |
Unique Elements | β1-β2 loop (dsDNA/ssRNA binding) | Disulfide bond (Cys230-Cys267) |
Tissue Expression | Brain, adipose tissue | Testes, lungs, spleen |
Despite shared catalytic machinery, FTO and ALKBH5 exhibit striking substrate preferences:
The erasure of m6A is an oxidative tour de force:
Substrate | FTO Activity | ALKBH5 Activity | Notes |
---|---|---|---|
m6A-ssRNA | High (Km ~2.5 μM) | High (Km ~1.8 μM) | Prefers GGACU motifs |
m6A-dsRNA | Low | None | ALKBH5 blocked by disulfide bond |
m³T (ssDNA) | Moderate | None | FTO-specific off-target activity |
Citrate inhibition | ICâ â >1 mM | ICâ â ~488 μM | TCA cycle intermediate 1 |
A landmark study resolved ALKBH5 bound to m6A-ssRNA (PDB: 7V4G), revealing how its structure enables RNA-specific demethylation 6 .
This structure revealed that m6A itself acts as a "conformational marker"âits presence remodels RNA structure, allowing ALKBH5 to discriminate between nearly identical sequences 6 .
Reagent | Function | Example/Notes |
---|---|---|
Recombinant Enzymes | Catalytic studies, inhibitor screening | ALKBH5 (74-294), FTO (32-326) 1 |
m6A-ssRNA Oligos | Substrate for activity assays | e.g., 5â²-GG(m6A)CU-3â² 6 |
2-Oxoglutarate (2OG) | Essential cofactor | Stabilizes Fe(II); consumed in reaction |
Citrate | Weak ALKBH5 inhibitor (ICâ â ~488 µM) | TCA cycle intermediate 1 |
ITC Assay Kits | Measure binding affinity (RNA/enzyme) | Kd values for substrate recognition 1 |
Crystallization Buffers | Structural studies | Ammonium phosphate + PEG 3350 6 |
Dysregulation of FTO/ALKBH5 is linked to disease through m6A-dependent RNA stability control:
The structures of FTO and ALKBH5 are more than molecular blueprintsâthey reveal how cells dynamically rewrite their RNA code. With their disulfide bonds, nucleotide-snaring loops, and metal-driven chemistry, these enzymes exemplify nature's precision in epigenetic regulation. Current efforts to target them (e.g., ALKBH5 inhibitors for cancer) now leverage these structural insights 4 8 . As we unravel how m6A remodels RNA conformation to guide erasers to their targets, we move closer to therapies that can "edit" RNA methylationâushering in a new era of epitranscriptomic medicine.
"The language of RNA is written in methyl marksâFTO and ALKBH5 are its erasers, but we are learning to rewrite it."